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There are no known biological markers or technologies to predict the
natural history of an individual CIN III. The probability of progression
is considered greater with the persistence of high-risk human papillo-
mavirus (HPV) infection and age. p53 polymorphism has been asso-
ciated with cervical carcinogenesis. Hormone-induced cervical cancer is
mediated by estrogen receptor (ER) and progesterone receptor (PR). In
cervical cancer, increased bcl-2 and Bax immunoreactivity is generally
associated with a better prognosis. The purpose of this study was to
evaluate the value of HPV 16 and HPV 18 typing and p53 codon poly-
morphism genotyping by polymerase chain reaction and ER, PR, bcl-2,
and Bax expression by immunohistochemistry in predicting the CIN III
clinical behavior of CIN III lesions. We studied the expression of these
prognostic factors in the CIN III adjacent to squamous cell microinva-
sive carcinomas of the cervix (MIC) from 29 patients with FIGO stage
IA1 cervical cancer and in 25 patients with CIN III and no documented
focus of invasion. In the MIC group, only the CIN III was considered at
least 2mm away from the microinvasive complex. The ER, PR, bcl-2, and
Bax immunoreactivity was scored as positive (>10% staining cells) and
negative (<10% staining cells). No significant difference was observed
between MIC and CIN III group concerning HPV infection and p53
polymorphism. The ER, PR, bcl-2, and Bax immunohistochemical
expression was stronger and more frequent in the CIN III group. After
multivariable analysis, coexpression of ER, PR, and bcl-2 was the only
independent factor in defining low risk of progression for CIN III. Our
study suggests that coexpression of ER, PR, and bcl-2 may be a useful
tool in identifying the CIN III lesions with low risk of progression to
cervical cancer.
KEYWORDS: cervical microinvasive carcinoma, CIN III, immunohistochem-
istry, prognosis.
Cervical cancer is one of the most frequent cancers
in women, with an estimated worldwide incidence
of about 371,000 new cases per year and an overall
5-year survival ranging from 44 to 66% for all clinical
stages(1).
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Invasive cancers are usually accompanied by CIN
III, and presumably this lesion precedes most carcino-
mas(2). The rate of CIN III progression is unknown,
but based on follow-up studies of untreated or incom-
pletely treated CIN III, one may assume that risk for
cancer progression may be as low as 20% to up to
70%, and regression rate may be as high as 32%(3,4). To
prevent invasive cervical cancer, a successful treat-
ment of high-grade CIN, particularly CIN III, is the
gold standard management(5). The surveillance sche-
dule for treated patients is not so well defined. Iden-
tifying a subset of patients with CIN III with low risk
for cancer progression may be helpful in clinical prac-
tice for rationalizing follow-up.
HPV infection is present in virtually all cancers and
is the strongest epidemiological factor for cervical
cancer development(6). Among women with cervical
cancer, HPV 16 is the most prevalent HPV type. When
determined by polymerase chain reaction (PCR), HPV
16 genoma accounts for more that half of the cases of
CIN III and invasive cervical cancer with variations
according to race and country(6—11).
Viral integration is important for cell transform-
ation and cervical carcinogenesis. In invasive carcino-
mas of the cervix, the genoma of HPV 16 and HPV 18
is integrated in up to 70% of the cases(12,13). When
viral integration occurs, the HPV genome breaks in
the E2 region resulting in loss of its suppressive func-
tion on E6 and E7. The E6 gene product of high-risk
HPV binds with high affinity to p53, inactivating it by
inducing degradation through a selective ubiquitin-
dependent proteolytic pathway, promoting uncon-
trolled cell proliferation and eventual development
of cervical neoplasia(14,15). Somatic and germ line
mutations of p53 are rarely detected in cervical can-
cers(16,17); however, at least 10 p53 polymorphisms
have been described in both coding and no-coding
regions of the gene(18). Storey et al.(19) were the first
to show that the risk for the development of HPV-
associated cervical cancer in white British women was
significantly higher for arginine homozygosity (Arg/
Arg) at codon 72 in the p53 amino acid sequence than
for arginine heterozygosity (Arg/Pro) and proline
homozygosity. Some studies are in agreement and
others have refuted these observations, and these con-
flicting results have been attributed to ethnic differ-
ences in allelic frequencies, sample size, selection bias
of controls, DNA source, and the methodology
used(20,21).
The HPV E7 protein binds to the Rb—E2F com-
plexes, releasing E2F protein, and targets Rb protein
for ubiquitin-dependent proteolysis(22). E2F-1, the
best-characterized member of the E2F family, acti-
vates the transcription of genes for S-phase and
induces apoptosis in the presence of functional p53
protein(23,24). Thus, during HPV infection, the pro-
apoptotic signals generated by E7 may be totally or
partially counterbalanced by E6 protein.
The product of the proto-oncogene bcl-2 may block
apoptosis. Overexpression of bcl-2 is generally asso-
ciated with a better prognosis in several malignancies
including cervical cancer(25—29), and increased Bax
immunoreactivity was described as a favorable prog-
nostic factor in cervical cancer(30—33).
An imbalance between HPV-induced cell prolifer-
ation and apoptosis may be not sufficient for the devel-
opment of invasive cervical cancer, and several
possible cofactors have been identified, including the
steroid hormones estrogen and progesterone. Most
cervical cancers arise in the transformation zone, an
area known as the most estrogen- and progesterone-
sensitive region of the cervix(34). Expression of estro-
gen receptors (ERs) and progesterone receptors (PRs)
has been reported to be a favorable prognostic factor
in breast cancer(35), endometrial carcinoma(36), ovarian
cancer(37,38), and cervical adenocarcinoma(38). In squa-
mous cell carcinoma of the cervix, ER and PR expres-
sion had minor prognostic value(39), but via their
receptors, estrogen and progesterone are involved in
cervical carcinogenesis(40) by increasing the genoma
expression of HPV 16 and HPV 18(41—43).
The purpose of this study was to evaluate the value
of HPV 16 and HPV 18 typing, p53 codon polymorph-
ism genotyping, and ER, PR, bcl-2, and Bax immuno-
histochemical expression as prognostic factors in CIN
III.
Patients and methods
Patient characteristics
For this study, two groups of material were selected
(i) MIC group — the CIN III of 30 patients with the
diagnosis of FIGO stage IA1 squamous cell carcinoma
of the cervix (MIC) diagnosed between 1996 and 1999;
(ii) CIN III group — the CIN III from the 30 first cases
with diagnosis of CIN III, with no documented inva-
sive focus, diagnosed by cone biopsy in 1998 were
also retrieved for comparative analysis. All cases
were diagnosed, treated, and were followed up at
the Gynecology Department of Portuguese Cancer
Institute of Coimbra. All patients had documented
HIV seronegativity, were not pregnant, and had no
history of drug addiction as well as no immunosup-
pressive therapy in the last 6 months.
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Two pathologists (LC and EC) reviewed all slides
from punch biopsy, conization, and hysterectomy,
and the pathological classification was obtained by
consensus between them according to the criteria for-
mulated by the World Health Organization. In the
MIC group, only the CIN III at least 2mm away
from the microinvasive complex was studied, and
from this group one case was excluded because the
material was considered not suitable for immunohis-
tochemistry. From the CIN III group, five cases were
excluded: one was lost to follow-up; one due to recur-
rent CIN III developed 6 months after treatment; one
had ASCUS Pap smear at the eighteenth month of
follow-up; and two were considered not suitable for
immunohistochemistry.
The diagnosis of MIC was obtained by conization in
27 (93.1%) cases and by incidental hysterectomy in
two (6.9%). In all cases of MIC, the hysterectomy was
the definitive treatment, and in the CIN III group,
15 (60.0%) patients were submitted to subsequent
hysterectomy and 10 (40.0%) patients remained in
follow-up.
All patients selected for this study had a follow-up
of at least 30 months, with no documented CIN or
invasive recurrence or abnormal Pap smear.
Tissue specimens
The specimens were formalin fixed and paraffin
embedded. From each, we selected the two more
representative blocks. For immunohistochemistry,
3-mm thick consecutive sections were cut from the
respective tumor block.
Detection and typing of HPV
HPV DNA was extracted according to standard pro-
tocols(44). Consensus primers for L1 gene were used
as described by Kleter et al.(45). Specific primers for
HPV 16 E6 gene were used, as described by Shibata
et al. (46) and specific primers for HPV 18 genes were
used as initially described by Tam and Chow(47).
Agarose gel electrophoresis then confirmed the speci-
ficity of the amplified DNA. Controls were always
used.
Detection of p53 codon 72 polymorphic genotypes
Three to six 10-m thick sections were cut onto histo-
logical slides from each case. p53 codon 72 Pro and
Arg genotypes were analyzed by allele-specific PCR
according to the method described by Storey et al.(19).
The PCR products were subjected to electrophoresis
on 1% agarose gel, using 1 0.04M tris-acetate-EDTA
(0.001M). Gelstar1 Nucleic Acid Gel Stain (BMA)
according to the manufacturer’s instructions then
stained the gel (CARYBREX Bioscience, Rockland, ME).
Bax and bcl-2 immunohistochemistry
The antigens were incubated with monoclonal mouse
antihuman bcl-2 (clone 124 (1/40), isotype IgG1;
Dako, Glostrup, Denmark) or polyclonal rabbit
antihuman Bax (1/500, Dako). To identify antigen—
antibody complexes, an immunoperoxidase method
employing an avidin—biotin (StreptABC/HRP) perox-
idase complex was used for bcl-2 (TechMate 500 Plus,
MSIP protocol, Vector Laboratories, Burlingame, CA),
and for Bax a catalyzed signal amplification (CSA)
system with CSA rabbit link was used. Peroxidase
activity was demonstrated by incubating the slides
in 3,30diahinobenzidine (DAB) (Dako) followed by
counterstaining with hematoxylin (Richard Allen,
Richland, MI) and mounted on a no-aqueous medium
(dibutilftalate xylol, DPX). Staining without antibody
was performed routinely as a negative control. As
positive controls, infiltrating lymphocytes were stained
for bcl-2 and Bax.
ER and PR immunohistochemistry
The antigens were incubated with monoclonal anti-
body Novocastra NCL-L-ER-6F11 (1/25) against ERs
and monoclonal antibody Novocastra NCL-L-PGR-
312 (1/25) against PR.
To identify antigen—antibody complexes, an immuno-
peroxidase method employing an avidin—biotin
(StreptABC/HRP) peroxidase complex (TechMate
500 Plus, MSIP protocol, Vector Laboratories) was
used. Peroxidase activity was demonstrated by incu-
bation of the slides in DAB (Dako) followed by coun-
terstaining with hematoxylin (Richard Allen) and
mounted using a no-aqueous medium (DPX). Positive
control was ER- and PR-positive breast cancer tissue,
and specific staining was observed as nuclear brown-
colored granules. Negative control was ER- and
PR-negative prostate cancer.
Evaluation of immunohistochemical results
All hemotoxylin and eosin (H&E) and immunostained
slides were independently reviewed by two observers
(LC and EC). In cases of discrepancy, a consensus was
always reached. Cytoplasm immunoreactivity specific
for bcl-2 and Bax and nuclear immunoreactivity spe-
cific for ER and PR was expressed in terms of the
percentage of cells exhibiting specific staining. In all
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cases, the intensity of staining was always stronger
as more cells were positively stained. A negative
staining was considered if less than 10% of the cells
showed specific immunoreactivity, independent of the
intensity of staining. Similarly, a positive staining was
considered if 10% or more of the cells showed specific
immunoreactivity. The distribution of the positive cells
in the neoplastic epithelium was also recorded. In all
cases, 500 cells were randomly counted.
Statistical analysis
Statistical analysis was computed at SSPS 10.0 for
Windows (IL). For comparing the mean age, we
used independent samples t-test. Chi-square and
Fisher’s exact test evaluated the differences in categor-
ical data. The significance was adjusted by computing
a binary logistic regression. A P value of <0.05 was
considered to reflect a significant difference.
Results
The results of HPV typing, the distribution of the
three genotypes of p53 as either Arg and Pro homo-
zygotes or Arg/Pro heterozygote, and the mean age
of the patients in both MIC group and CIN III group
are outlined in Tables 1, 2, and 3, respectively.
Immunostaining for ER and PR was specially local-
ized to nuclear envelope and occasionally to the cyto-
plasm (Figs. 1 and 2) and all cases that stained, stained
with lower intensity than control. Immunostaining
for bcl-2 and Bax was always localized to the cell
cytoplasm (Figs. 3—5) and occasionally as a finely
granular pattern.
In CIN III, the ER, PR, bcl-2, and Bax immunostain-
ing usually involved all epithelial layers, but the
expression of bcl-2 (Fig. 3) was more intense at the
basal two-thirds of the neoplastic epithelium on both
CIN III group and MIC group, and the Bax expression
(Fig. 4) was stronger at the superficial two-thirds.
The immunohistochemical results for ER, PR, bcl-2,
and Bax are outlined in Table 3. After adjustment, by
multinomial logistic regression, only coexpression of
ERþPRþ bcl-2 remained as independent risk factors
in defining low risk of progression for CIN III. We
computed a sensitivity of 100% and a specificity of
64.4% for ERþPRþ bcl-2 as a marker for low risk of
progression in CIN III.
For both the MIC group and the CIN III group,
there was no statistically significant difference
between ERþPRþ bcl-2-positive immunostaining
and HPV type (P¼ 0.290) and p53 codon 72 poly-
morphism (P¼ 0.755).
Discussion
It has not been possible to predict the natural history
of a particular CIN III, even after adequate treatment.
Based on the reports of women with CIN III who
inadvertently were not treated, we may assume that
the progression rate may be high, and this is the
reason for treating all women with CIN III(3,4). After
treatment, the best management policy in follow-up is
not consensual. For the detection of persistent and
recurrent high-grade CIN, colposcopy with directed
biopsy is a good tool(48), but is very expensive, time
consuming, and limited to some medical centers.
Cytology is not very sensitive(49,50) and to compensate
for its poor sensitivity, clinicians have traditionally
used serial repeat cytology. HPV DNA testing for
oncogenic HPV types seems comparable to repeated
cytology(51). For treatment surveillance, the negative
predictive value of HPV testing approaches 100%, but
the specificity is low, and this means that oncogenic
HPV DNA may persist posttreatment without cytolo-
gical or histological evidence of disease(52,53).
This study was designed to find out a useful mar-
ker to identify a subset of CIN III with low risk of
progression to invasive cancer. The immunohisto-
chemical methodology is widely used worldwide.
For this reason, we have chosen this technology to
evaluate ER, PR, bcl-2, and Bax expression. Formalin-
fixed, paraffin-embedded tissue sections with micro-
wave treatment was employed, which is an effective
method to expose antigens and advantageous to
Table 1. HPV infection
MIC group [n (%)] CIN III group [n (%)]
HPV 16 26 (89.7) 17 (68.0)
HPV 18 0 (0.0) 0 (0.0)
Other HPV 3 (10.3) 8 (32.0)
Total 29 (100) 25 (100)
MIC group: CIN III at least 2mm away from microinvasive
complex from patients with the diagnosis of MIC; CIN III
group: CIN III from patients with diagnosis of CIN III.
Table 2. p53 codon 72 polymorphism genotypes
MIC group [n (%)] CIN III group [n (%)]
Arg-Arg 23 (79.3) 18 (72.0)
Arg-Pro 4 (13.8) 4 (16.0)
Pro-Pro 2 (6.9) 3 (12.0)
Total 29 (100) 25 (100)
MIC group: CIN III at least 2mm away from microinvasive
complex from patients with the diagnosis of MIC; CIN III
group: CIN III from patients with diagnosis of CIN III.
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observe a wider area of tissue sections(54). The HPV
typing and p53 Arg/Pro polymorphism were also
studied, as they could be possible confounding vari-
ables.
We evaluated the CIN III in 29 patients with MIC,
and 25 patients with CIN III were selected as a control
group. Probably, this control group belongs to a sub-
set of CIN III with low risk for progression, because
all patients had at least 30 months of follow-up with-
out progression or recurrence and no abnormal Pap
smear during the follow-up period.
Our results showed that women with MIC were
about 5 years older than patients with CIN III group,
which is in accordance with a Costa Rica study that
suggests that CIN III progresses to subclinical cancer
in about 5 years and that symptomatic cancer arises 4
to 5 years later(55).
We reported a high prevalence of HPV 16 infection
in both the studied groups, in agreement with a
worldwide study conducted by Bosh et al.(56) who
found a high prevalence of HPV 16 in cervical cancer
in Europe. Identical study on a Portuguese population
detected HPV 16 DNA sequences by PCR in 83.3% of
squamous cell cervical cancers(57).
There are no published studies on p53 polymorph-
ism in Portuguese population, but the frequency of
homozygous arginine p53 polymorphism has been
Table 3. Age, HPV 16 and ER, PR, bcl-2, and Bax immunohistochemistry positive results
MIC group (29 cases) CIN III group (25 cases) P Adjusted P
Mean age (years) 41.79 8.89 36.04 10.67 0.035 0.267
ER positive [n (%)] 10 (34.5) 11 (44.0) 0.579 —
PR positive [n (%)] 8 (27.6) 13 (52.0) 0.094 —
Bcl-2 positive 16 13 1.000 —
Bax positive 27 25 0.493 —
ERþPR positive 3 (10.3) 10 (40.0) 0.023 0.646
Bcl-2þBax positive 14 (48.3) 13 (52.0) 1.000 —
ERþPRþBcl-2 positive 0 (0.0) 9 (36.0) 0.0004 0.001
ERþPRþBax positive 3 (10.3) 10 (40.0) 0.023 0.646
MIC group: CIN III at least 2mm away from microinvasive complex from patients with the diagnosis of MIC; CIN III group: CIN III
from patients with diagnosis of CIN III. ER, estrogen receptor; PR, progesterone receptor.
Fig. 1. This figure shows a CIN III with nuclear staining positive for
ER ( 40).
Fig. 2. This figure shows a CIN III with nuclear staining positive for
PR ( 40).
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reported as higher as 50% in many Caucasian
groups(19,20,58,59) in accordance with the high fre-
quency detected in our samples. We found that p53
polymorphism has no value in predicting progression
of CIN III which is in agreement with previous stud-
ies reporting that p53 polymorphism has no prog-
nostic significance in cervical cancer(60,61). In the
present study, the p53 polymorphism was not related
to HPV type, as reported by others(60—62).
Clinical evidence that estrogens and progesterone
may have a carcinogenic effect in HPV-infected cervix
was recently reported in two multicentric case-control
studies(63,64). Our ER- and PR-positive results are
similar to previous studies relying on ER and PR
detection in cervical cancer(39,65—69). However, wide
variation exists between ER and PR reports on cervical
cancer probably due to the differences in the methods
employed, sample preparation, and different cut-off
values for positive results. We found a significantly
higher positive coexpression of ER and PR in the
CIN III group than in CIN III of the MIC group. As
induction of PR is one of the best-recognized
responses to estrogen in target tissues(70,71), we can
hypothesize that in the MIC group, most of ER may
have no or reduced functional activity. The finding
that in all cases in the MIC group with coexpression of
ER and PR, the ER staining was stronger and
Fig. 3. This figure shows a CIN III with cytoplasm basal staining
positive for bcl-2 ( 40).
Fig. 4. This figure shows a CIN III with cytoplasm diffuse staining
positive for bcl-2 ( 40).
Fig. 5. This figure shows a CIN III with cytoplasm granular staining
positive for Bax ( 40).
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expressed in more cells than PR staining, which is not
true for CIN III group, supports this idea. Moreover,
coexpression of ER, PR, and bcl-2 was observed in
CIN III group but not in MIC group, which agrees
with previous studies suggesting an estrogen-depend-
ent upregulation of bcl-2(72,73).
Several studies have shown that HPV gene expres-
sion can be increased in response to both estrogen and
progesterone stimulation(41—43). Webster et al.(74)
reported that estrogen and progesterone increase the
level of apoptosis induced by HPV 16 E2 and E7
proteins, and they suggest that in the presence of E2,
these hormones may be protective against cervical
cancer via their upregulation of apoptotic cell death.
Apoptosis is regulated by a balanced interaction of
genes, among which bcl-2 and Bax are the most
important(75—77). The ratio between Bax and bcl-2
gene expression determines the susceptibility of the
cell to apoptosis(78—80). In cells with Bax overexpres-
sion, the susceptibility to apoptosis is enhanced and,
on the contrary, an excess of bcl-2 protein appears to
be associated with carcinogenesis(80). In the present
study, both in MIC and CIN III groups, the expression
of Bax was always stronger and present in more cells
than bcl-2 staining, suggesting a driving stimulus
toward apoptosis. However, Bax immunostaining
has shown no significant differences in both CIN III
and cervical cancer(81—83), suggesting that Bax expres-
sion is not always required for induction of apoptosis
in cervical neoplastic cells(84).
Some authors found a stronger bcl-2 immunostain-
ing in CIN III than in cervical cancer, supporting the
hypothesis that the loss of bcl-2 expression occurs
during the evolution of the malignant pheno-
type(81,82,85—87). Others did not find this association(83).
These studies have reported that the progression of
CIN is accompanied by increasing bcl-2 protein over-
expression and suggest that the progression of CIN is
reflected by the bcl-2 expression levels. In CIN III,
bcl-2 tends to extend into the higher layers of the epi-
thelium, preventing apoptosis and facilitating prolif-
eration. It is difficult to explain why bcl-2 expression
is lost in invasive cervical cancer, but wemay speculate
that, after neoplastic transformation, apoptosis may
not be under the normal control mechanisms. In our
study, the pattern of bcl-2 staining in studied CIN III
of MIC group and CIN III group was similar, prob-
ably because both the groups of CIN III were closest
on apoptosis control than with low-grade CIN.
In conclusion, our study suggests that positive
immunohistochemical coexpression of ER, PR, and
bcl-2 may be a useful tool in identifying a subset of
patients with CIN III that have a low risk for cancer
progression, independent of the patient’s age and
HPV status. Further studies performed in different
populations and in different laboratories must vali-
date these data.
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